Literature DB >> 24930922

Use of polypharmacy and self-reported mood in outpatients with bipolar disorder.

Mazda Adli1, Peter C Whybrow, Paul Grof, Natalie Rasgon, Laszlo Gyulai, Christopher Baethge, Tasha Glenn, Michael Bauer.   

Abstract

Objective. As polypharmacy is routinely used for the treatment of bipolar disorder, the relation between the daily number of psychotropic medications and self-reported mood was investigated. Method. Eighty patients (35 men and 45 women) with a diagnosis of bipolar disorder I or II, recruited from academic centres, entered their mood, sleep, and psychotropic medications for 3 months into ChronoRecord software. A total of 8662 days of data was received (mean 114.7 days/per patient). Results. Seventy-nine patients took a mean of 3.8 medications daily (SD 1.7; range 1-9); one took none. Of these patients, 73 (92.4%) took mood stabilizers, 47 (58.8%) took antidepressants, 31 (38.8%) took antipsychotics, 34 (42.5%) took benzodiazepines and 17 (21.1%) took thyroid hormones. Patients reporting normal mood more frequently took fewer medications; the Pearson correlation coefficient between the number of medications and the percent of days normal was -0.481 (P < 0.001). Grouping by number of medications, ANOVA analysis showed those taking fewer medications reported normal mood more frequently (P<0.001). Conclusion. Combination treatment regimens are routinely prescribed for bipolar disorder. Patients reporting normal mood more frequently took a fewer number of daily medications. Studies are needed to better identify those patients who would benefit from polypharmacy and to optimise the combinations of medications for patients with refractory disorder.

Entities:  

Keywords:  Bipolar disorder; combination therapy; polypharmacy; self-reported mood

Year:  2005        PMID: 24930922     DOI: 10.1080/13651500510029200

Source DB:  PubMed          Journal:  Int J Psychiatry Clin Pract        ISSN: 1365-1501            Impact factor:   1.812


  8 in total

1.  Evidence-Based Principles for Bipolar Disorder Treatment.

Authors: 
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

Review 2.  Complex Combination Pharmacotherapy for Bipolar Disorder: Knowing When Less Is More or More Is Better.

Authors:  Joseph F Goldberg
Journal:  Focus (Am Psychiatr Publ)       Date:  2019-07-16

3.  Daily electronic monitoring of subjective and objective measures of illness activity in bipolar disorder using smartphones--the MONARCA II trial protocol: a randomized controlled single-blind parallel-group trial.

Authors:  Maria Faurholt-Jepsen; Maj Vinberg; Mads Frost; Ellen Margrethe Christensen; Jakob Bardram; Lars Vedel Kessing
Journal:  BMC Psychiatry       Date:  2014-11-25       Impact factor: 3.630

Review 4.  Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review.

Authors:  Michele Fornaro; Domenico De Berardis; Ann Sarah Koshy; Giampaolo Perna; Alessandro Valchera; Davy Vancampfort; Brendon Stubbs
Journal:  Neuropsychiatr Dis Treat       Date:  2016-03-31       Impact factor: 2.570

Review 5.  Electronic monitoring of self-reported mood: the return of the subjective?

Authors:  Abigail Ortiz; Paul Grof
Journal:  Int J Bipolar Disord       Date:  2016-11-29

6.  A New Treatment Protocol of Combined High-Dose Levothyroxine and Repetitive Transcranial Magnetic Stimulation for the Treatment of Rapid-Cycling Bipolar Spectrum Disorders: A Cohort Evaluation of 55 Patients.

Authors:  Antonis C Zamar; Christos Kouimtsidis; Abbi Lulsegged; Robin Roberts; Theodoros Koutsomitros; Daniel Stahl
Journal:  J Clin Med       Date:  2022-09-30       Impact factor: 4.964

Review 7.  Electronic self-monitoring of mood using IT platforms in adult patients with bipolar disorder: A systematic review of the validity and evidence.

Authors:  Maria Faurholt-Jepsen; Klaus Munkholm; Mads Frost; Jakob E Bardram; Lars Vedel Kessing
Journal:  BMC Psychiatry       Date:  2016-01-15       Impact factor: 3.630

8.  Mechanisms Underpinning the Polypharmacy Effects of Medications in Psychiatry.

Authors:  Chiara C Bortolasci; Briana Spolding; Edward Callaly; Sheree Martin; Bruna Panizzutti; Srisaiyini Kidnapillai; Timothy Connor; Kyoko Hasebe; Mohammadreza Mohebbi; Olivia M Dean; Sean L McGee; Seetal Dodd; Laura Gray; Michael Berk; Ken Walder
Journal:  Int J Neuropsychopharmacol       Date:  2018-06-01       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.